All Words, No Action Make Europe an Unfriendly Place, says Daniel Vasella
Executive Summary
The chairman and CEO of Novartis is moving the group's global research hub from Switzerland to Cambridge, MA. Daniel Vasella tells In Vivo Europe why he's joined the list of European defectors, and what he thinks the future holds for the European industry.
You may also be interested in...
Radiopharmaceuticals: A New Frontier In Precision Cancer Therapy
Growing interest in radioligand-based cancer therapies reflects the class’s unique advantages – including the ability to “see what you treat.”
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
What Next In Oncology?
Oncology dominates pharma sales and pipeline league tables. But where is the next Keytruda?